Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
AssigneeBiogen Idec MA Inc.
InventorsJames G Barsoum, Albert X Qin
Life of this patent
Estimating the term…
Abstract
Methods and pharmaceutical compositions for modifying cells of a mammalian recipient with DNA encoding a secreted protein such as human interferon in situ are provided. The methods include forming a secreted protein expression system in vivo or ex vivo and administering the expression system to the mammalian recipient. The expression system and methods are useful for the localized and systemic delivery of interferons in situ.
Claims31
A method for treating cancer by in vivo interferon-β gene therapy comprising the steps of:
- parenterally administering to a subject a viral vector comprising a gene that encodes interferon-β protein, and
- allowing said interferon-β protein to be expressed from said gene in said subject in an amount sufficient to cause cancer regression or inhibition of cancer growth,
- wherein said viral vector is selected from the group consisting of an adenoviral vector, a lentiviral vector, a baculoviral vector, an Epstein Barr viral vector, a papovaviral vector, a vaccinia viral vector, and a herpes simplex viral vector, and
- wherein if said viral vector is an adenoviral vector, then said subject is not exposed to a nucleic acid encoding a selectable marker gene.
A method for treating cancer by in vivo interferon-β gene therapy comprising the steps of:
- parenterally administering to a subject a replication-defective viral vector comprising a gene that encodes interferon-β protein, and
- allowing said interferon-β protein to be expressed from said gene in said subject in an amount sufficient to cause cancer regression or inhibition of cancer growth,
- wherein said viral vector is selected from the group consisting of an adenoviral vector, a lentiviral vector, a baculoviral vector, an Epstein Barr viral vector, a papovaviral vector, a vaccinia viral vector and a herpes simplex viral vector, and
- wherein if said viral vector is an adenoviral vector, then said subject is not exposed to a nucleic acid encoding a selectable marker gene.
A method for treating cancer by in vivo interferon-β gene therapy comprising the steps of:
- administering to a subject a viral vector comprising a gene that encodes interferon-β protein, and
- allowing said interferon-β protein to be expressed from said gene in said subject in an amount sufficient to cause cancer regression or inhibition of cancer growth by induction of a systemic anti-tumor immune response,
- wherein said viral vector is selected from the group consisting of an adenoviral vector, a lentiviral vector, a baculoviral vector, an Epstein Barr viral vector, a papovaviral vector, a vaccinia viral vector and a herpes simplex viral vector, and
- wherein if said viral vector is an adenoviral vector, then said subject is not exposed to a nucleic acid encoding a selectable marker gene.
Dependencies are inferred from the claim text.